Tegal Makes Strategic Investment in NanoVibronix, Innovator in Global Wound Care and Catheter Markets
29 Novembro 2011 - 10:01AM
Business Wire
Tegal Corporation (NASDAQ:TGAL) today announced that it has made
a $300,000 strategic investment in NanoVibronix Inc., a private
company that develops medical devices and products that implement
its proprietary therapeutic ultrasound technology.
NanoVibronix is a medical device company focused on creating
products utilizing its proprietary low-intensity surface
acoustic wave (SAW) technology. The company's unique, patented
approach enables the transmission of low-frequency, low-intensity
ultrasound waves through a variety of soft, flexible materials,
including skin and tissue, enabling low-cost, breakthrough devices
targeted at large, high-growth markets.
NanoVibronix is developing a series of products directed at the
treatment of chronic, non-healing wounds. The global wound care
market is estimated to reach $22.8 billion by 2017, of which
approximately one-third is addressed by advanced wound care
products, according to a report recently published by Global
Industry Analysts, Inc., a research group. The growth of the market
is being fueled by an aging population and the rapidly increasing
incidence of diabetes world-wide.
The company's first product, PainShieldTM MD has gained FDA
clearance and CE Mark certification in Europe, and is marketed for
the treatment of tendonitis, muscle pain and trigeminal neuralgia.
Additionally, the company has developed a family of disposable
ultrasound devices to treat catheter-associated infection and
injury, accomplished by preventing biofilm formation and decreasing
the friction between the catheter and body tissues. The UroShieldTM
product is currently CE mark certified, and is the subject of
several independent clinical trials being conducted by leading
researchers in Europe and the Middle East.
“Our investment in NanoVibronix expands the Tegal portfolio to
new markets and new commercial horizons,” said Mr. Mika.
“NanoVibronix is a technology leader in the application of surface
acoustic waves in the treatment of wounds and the prevention of
infection in indwelling catheters. Under the leadership of Dr.
Harold Jacob, NanoVibronix Chief Executive Officer, the company has
demonstrated the scientific merit, safety and efficacy of devices
using this technology to address the therapeutic needs of patients
and clinicians.”
“Tegal’s investment and management expertise are critical to
accelerating the growth of NanoVibronix,” said Dr. Jacob. “We are
extremely pleased to partner with Tegal as we take the next step in
our corporate growth plan.”
About Tegal
Since its founding in 1972, Tegal Corporation has been dedicated
to the development and application of emerging technologies. Often
on the forefront of major inventions, Tegal’s process and capital
equipment know-how enabled the development and manufacturing of
leading-edge devices – from early microprocessors to advanced
memory and LEDs, as well as to newest filtering and sensing devices
that are present in the most advanced smart phones. Tegal draws
upon its historic market and technology leadership in
semiconductors and MEMS devices to engage in the promotion of other
emerging technologies, including PV-based solar power generation
and medical devices. Tegal is actively evaluating opportunities for
partnerships with diversified technology-based companies in order
to exploit our shared experience and to enhance our value as a
public company. Tegal is headquartered in Petaluma, California.
Please visit us on the web at www.tegal.com.
About NanoVibronix
NanoVibronix, located in Nesher Israel, develops products that
implement its proprietary therapeutic ultrasound technology. The
company's products are used in the area of active wound care to
treat chronic wounds and for soft-tissue healing. The company has
also developed a unique line of catheter based disposable
ultrasound devices designed to treat catheter associated injury
including pain, discomfort and biofilm formation. The first two
products in this category are the UroShield™ for in-dwelling
urinary catheters and NG-Shield™ for in-dwelling Nasogastric tubes.
More information may be obtained at www.nanovibronix.com.
Tegal (NASDAQ:TGAL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Tegal (NASDAQ:TGAL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024